{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Feola S"],"funding":["Helsinki Institute of Life Science","Horizon 2020 Framework Programme"],"pagination":["E1660"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7352969"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(6)"],"pubmed_abstract":["According to the latest available data, cancer is the second leading cause of death, highlighting the need for novel cancer therapeutic approaches. In this context, immunotherapy is emerging as a reliable first-line treatment for many cancers, particularly metastatic melanoma. Indeed, cancer immunotherapy has attracted great interest following the recent clinical approval of antibodies targeting immune checkpoint molecules, such as PD-1, PD-L1, and CTLA-4, that release the brakes of the immune system, thus reviving a field otherwise poorly explored. Cancer immunotherapy mainly relies on the generation and stimulation of cytotoxic CD8 T lymphocytes (CTLs) within the tumor microenvironment (TME), priming T cells and establishing efficient and durable anti-tumor immunity. Therefore, there is "],"journal":["Cancers"],"pubmed_title":["Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process."],"pmcid":["PMC7352969"],"funding_grant_id":["681219","none"],"pubmed_authors":["Martins B","Cerullo V","Feola S","Chiaro J"],"additional_accession":[]},"is_claimable":false,"name":"Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process.","description":"According to the latest available data, cancer is the second leading cause of death, highlighting the need for novel cancer therapeutic approaches. In this context, immunotherapy is emerging as a reliable first-line treatment for many cancers, particularly metastatic melanoma. Indeed, cancer immunotherapy has attracted great interest following the recent clinical approval of antibodies targeting immune checkpoint molecules, such as PD-1, PD-L1, and CTLA-4, that release the brakes of the immune system, thus reviving a field otherwise poorly explored. Cancer immunotherapy mainly relies on the generation and stimulation of cytotoxic CD8 T lymphocytes (CTLs) within the tumor microenvironment (TME), priming T cells and establishing efficient and durable anti-tumor immunity. Therefore, there is ","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jun","modification":"2025-06-01T02:36:01.978Z","creation":"2020-11-19T16:52:18Z"},"accession":"S-EPMC7352969","cross_references":{"pubmed":["32585818"],"doi":["10.3390/cancers12061660"]}}